Abnormal Hypermethylation of the VDAC2 Promoter is a Potential Cause of Idiopathic Asthenospermia in Men

Aiming Xu1,*, Yibo Hua1,*, Jianzhong Zhang1,*, Wei Chen1, Kai Zhao1, Wei Xi2, Hainan Wang1, Jianzheng Fang1, Shifeng Su1, Min Tang1, Bianjiang Liu1,3 & Zengjun Wang1,3

This study aimed to explore the association between the methylation status of the VDAC2 gene promoter region and idiopathic asthenospermia (IAS). Twenty-five IAS patients and 27 fertile normozoospermia (NZ) were involved. GC-2spd cells were treated with different concentrations of 5-aza-2′-deoxycytidine (5-Aza-CdR) for 24 h and 48 h. qRT-PCR was conducted to reveal whether or not VDAC2 expression was regulated by methylated modification. A dual-luciferase activity detection was used to verify VDAC2 promoter activity in GC-2spd cells. Bisulphite genomic sequence was used to analyse DNA methylation of the VDAC2 promoter. The results showed that VDAC2 expression was significantly increased after treated with 5-Aza-CdR. A strong activity of the promoter (−2000 bp to +1000 bp) was detected by dual-luciferase activity detection (P < 0.05). The bisulphite genomic sequencing and correlation analysis showed that sperm motility was positively associated with the methylation pattern of uncomplete methylation and mild hypermethylation, and negatively related to the percentage of moderate methylation. In conclusion, high methylation of the VDAC2 promoter Cpgs could be positively correlated with low sperm motility. Abnormal methylation of VDAC2 promoter may be a potential cause to idiopathic asthenospermia.

Approximately 50–80 million people worldwide are affected by infertility; of these cases, 50% are caused by male factors and most of them have asthenospermia. Varicoceles1, prostatitis2, and genital hypoplasia3 also result in low sperm motility. Idiopathic asthenospermia (IAS) is a disease without clear causes and is detected after regular examination and laboratory tests; IAS accounts for 30% of patients affected by male factors. According to the World Health Organization (WHO), the most defining symptom of IAS is normal sperm parameters except for low sperm motility4-5. Spermatogonium in testis and epididymis starts to mature to primary spermatocytes, secondary spermatocytes, and then sperm cells. Functional sperm contain a series of complex regulations, including gene expression, histone methylation, acetylation and promotion of sperm differentiation and maturation by microRNAs6. Abnormal protein expression and epigenetic modification changes may negatively affect sperm motility and morphology, thereby inducing male infertility. Abnormal regulation in spermatogenesis is a common aetiological factor of IAS.

Voltage-dependent anion channels (VDACs), also known as the mitochondrial porin protein, are pore-forming activators in the extract of Paramecium tetraurelia mitochondria7,8. VDAC has 3 subtypes (VDAC1, VDAC2, and VDAC3), which are approximately 70% identical and encode 3 different proteins9,10. Cheng et al. stated that VDAC2 is embryonically lethal and anti-apoptotic; this gene has gained increased research attention because of its roles during various physiological phenomena11. As the ‘gatekeeper’ of mitochondria, VDAC2 regulates and controls the transport of adenosine triphosphate/adenosine diphosphate (ATP/ADP), calcium ion (Ca2+) and nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide (NAD/NADH)12–14. At low voltages (<10 mV), VDAC is stable in a long-lived open state and allows macromolecular solutes, such as

1Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
2Department of Urology, Zhongshan Hospital affiliated to Fudan University, Shanghai 200032, China. 3State Key Laboratory of Reproductive Medicine, Nanjing medical University, Nanjing 210029, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to B.L. (email: bjliu@njmu.edu.cn) or Z.W. (email: zengjunwang@njmu.edu.cn)
ATP, to succinate across the planar bilayer membranes; at high positive or negative potentials (>40 mV), VDAC presents in multiple states, creating passages for select ions and proteins\(^{15,16}\).

VDAC2 plays an important role in spermatogenesis and male infertility\(^{17}\). It is abundant in the mitochondria outer dense fibers, which are close to the dynein light chain Tctex-type 1; it also regulates sperm motion and sperm tail structural integrity through interaction with Tctex or microtubule-associated proteins\(^{15,18,19}\). Human sperm was co-incubated with anti-VDAC antibody for 3 h, and the results indicated that the straight-line velocity (VSL), curvilinear velocity (VCL), and average path velocity (VAP) of spermatozoa were decreased via Ca\(^{2+}\) transmembrane flow inhibition\(^{18}\). Hence, abnormal VDAC2 expression is a potential cause of low sperm motility.

In our previous studies, we collected normal human adult semen samples and demonstrated, for the first time, that VDAC2 is located in human spermatozoa, specifically in sperm flagellate\(^{20}\). Furthermore, other studies have reported the expression profiles of different VDAC subtypes in mRNA in ejaculated spermatozoa from participants with normozoospermia (NZ) and patients with IAS; results found that infertility in male patients with IAS was correlated with VDAC2 expression \(^{17,21}\). However, just like the unclear molecular mechanism in VDAC3-lacking mice with normal parameters except for progressive motility, the underlying mechanism remains unclear\(^{22}\).

In this study, we explored the different methylation statuses of the VDAC2 gene between normal spermatozoa and asthenospermia. The relationship between sperm parameters and methylation level was determined to propose potential pathogenesis and promote clinical therapy for IAS.

### Results

#### Patient Characteristics.

Two separate groups, 27 participants with NZ and 25 with IAS, were recruited in the study; the mean ages of the 2 groups were 28 ± 5.56 and 28 ± 3.52 years, respectively. Sperm parameters, except for rapid sperm progressive motility and total motility (66.01 ± 8.72 and 18.75 ± 7.26, respectively; \(P < 0.01\)) were not significantly different between the 2 groups (Table 1).

#### Gene VDAC2 was Associated with Methylation Modification Status.

After 48 h of treatment with 5, 10, and 15 \(\mu\text{mol}/\text{L} 5\text{-aza}-2'\text{-deoxycytidine (5-Aza-CdR)}\) (Sigma Chemical Co., St. Louis, MO, USA), the total RNA of GC 2-spdk cells was extracted, reversed, and subjected to real-time quantitative polymerase chain reaction (qRT-PCR) assessment. VDAC2 gene expression significantly increased with increasing 5-Aza-CdR dosage. Furthermore, VDAC2 expression levels increased about 3-fold after treatment with 15 \(\mu\text{mol}/\text{L} 5\text{-aza}-\text{CdR} \) for 48 h compared to those in cells cultivated without 5-Aza-CdR (\(P < 0.05\)) (Fig. 1A). This finding indicates that demethylation enhanced VDAC2 expression.

### Table 1. Sperm characteristics of the analysed patient cohort.

| Type   | Number | Age (year) | Motility (%)* | Concentration (\(\times 10^5\)) | Volume (ml) |
|--------|--------|------------|---------------|-------------------------------|-------------|
| NZ     | 27     | 28 ± 5.56  | 66.01 ± 8.72  | 123.85 ± 48                   | 3.16 ± 1.03 |
| IAS    | 25     | 28 ± 3.52  | 18.75 ± 7.26  | 120.08 ± 38.64                | 3.65 ± 1.88 |

Data were presented as means ± SD, groups with different superscripts differ significant (\(P < 0.05\) by ANOVA). NZ: normozoospermia; IAS: idiopathic asthenospermia; *\(P < 0.05\).
Strong Promoter Activity in the VDAC2 Prognostic Region —2000 bp to +1000 bp. In our previous study, strong promoter activity was detected by dual-luciferase reporter assay; hence, the prognostic region —2000 bp to +1000 bp of VDAC2 could regulate the repression of VDAC2 expression (Fig. 1B).

CpGs (—1337 bp to —1059) may be a Potential Methylated Regulatory Region. We used one DNA sample to be modified with sodium bisulphite to select potential research targets from five predicted CpG islands discovered by CpGplot (Fig. 2A–E). The clone numbers were related with the DNA content, but it did not affect the credibility of our results. However, only CpGs (—1337 bp to —1059 bp) could be methylated after modification with sodium bisulfite (Fig. 2A), which might be a potential methylated regulatory region for sperm motility. Abnormal methylation of CpGs (—1337 bp to —1059 bp) may cause IAS.

Methylation status of the VDAC2 promoter. In NZ, the percentages of clones with complete unmethylation, mild hypermethylation, and moderate hypermethylation of VDAC2 promoters were 83.65% ± 5.51%, 8.73% ± 1.38%, and 7.62% ± 5.68%, respectively. In IAS, the corresponding percentages were 76.02% ± 6.94%, 7.14% ± 1.86%, and 16.62% ± 8.27%, respectively (P = 0.005, 0.02, and 0.003, respectively; Fig. 3A–C). One patient in the IAS group presented severe hypermethylation, but none did in the NZ group. Among 14 CpGs, approximately 60% (8/14) of the CpG island exhibited a higher methylation status than the other islands (Fig. 3D). Additional information on VADC2 promoter methylation in the 2 groups is shown in Fig. 3A and B and Table 2.

Correlation Analysis Between Methylation Status and PR%. The levels of the percentage of progressive sperm ratio (PR%) were positively correlated with the percentages of complete unmethylation (r = 0.48; P < 0.05) (Fig. 4A) and mild hypermethylation (r = 0.41; P < 0.05) (Fig. 4B). Moreover, the level of progressive sperm was negatively correlated with moderate hypermethylation (r = —0.65; P < 0.05) (Fig. 4C, Table 3). However, methylation status was not correlated with age, semen volume, and sperm liquefaction times (Table 3).

Discussion
In this study, we assessed genome demethylation by treating GC-2spd cells with 5-Aza-CdR. VDAC2 mRNA expression was compared between GC-2spd cells with and without 5-Aza-CdR through qRT-PCR analysis, and predicted the VDAC2 promoter region. After constructing plasmids containing the VDAC2 gene promoter, dual-luciferase activity was detected to verify the activity of the VDAC2 promoter region in GC-2spd cells. The extract of 52 sperm genomic DNA samples was subjected to bisulphite sequencing through PCR to analyze the DNA methylation of the VDAC2 promoter and determine the causes of down-regulated VDAC2 mRNA expression in IAS.

The VDAC2 protein is involved in many physiological functions, such as anti-apoptosis11, metabolite transport, spermatogenesis15, and oogenesis23. In the present study, the high expression of VDAC2 mRNA in the
demethylation group indicated that VDAC2 expression was associated with the methylation status of the promoter regions; however, whether hypermethylation leads to down-regulation of the VDAC2 protein remains unknown. The VDAC2 protein contains 9 cysteines, removal or modification of which can alter channel function in human. For example, specific modification of zinc finger cysteines with methyltransferase activity could abolish ubiquitin-chain binding of the Npl4 zinc finger (NZF) domains in TAB2/3, thereby disrupting host NF-kB signaling. During methylation, where nucleophilic attack of cytosine C5 on the S-adenosyl-L-methionine methyl group occurs, a covalent bond between Cys81-S− and cytosine C6 was rapidly formed; this bond can form and break reversibly. Based on the conserved cysteine components at corresponding regions in VDAC2, we speculated that an analogous change in the thiol status upon oxidative stress can lead to the closure of VDAC2 channels. Therefore, methylation in the CpGs of the VDAC2 promoter region, which results in down-regulation of the VDAC2 protein or dysfunction of cysteine components, must be further studied.

Vector construction is an important tool for molecular biological processes, including renovation of known carrier polyclonal sites and functional components, such as promoters, enhancers, and biomarkers. This study was the first to construct the vector of the VDAC2 gene promoter and lays a solid foundation for further studies on the transcriptional activity of the promoter region and nuclear promoter regions and the transcriptional regulatory mechanism of VDAC2. Considering the difficulty in acquiring human spermatocytes, we transfected the vector plasmid into the mouse spermatogenic GC-2spd cells. Strong activity of the promoter (−2000 bp to +1000 bp) was detected by dual-luciferase activity analysis (P < 0.05). Based on previous studies, we suggest that abnormal methylation of the VDAC2 promoter region causes either a decrease in the expression of VDAC2 mRNA or a functional defect, leading to changes in sperm motility and male infertility.

In this study, our results showed that clones with <80% methylation (i.e., complete unmethylation, mild hypermethylation, and moderate hypermethylation) of VDAC2 promoter were found in both two groups, whereas clones with >80% methylation (i.e., severe hypermethylation) occurred only in the IAS group. We further compared the correlation of different methylation categories of VDAC2 promoter region and sperm motility. In complete unmethylation or mild hypermethylation, sperm motility improved with increasing degree of methylation, especially in the situation of complete unmethylation. The acceleration rate of progressive motility decreased in mild methylation sperm compared with unmethylation sperm (as shown in Fig. 4A and B, with a slope of 0.0004 versus 0.0017). Meanwhile, the slope for severe methylation sperm was −0.0028, which was less than the slope for mild methylation sperm (as shown in Fig. 4B and C, with a slope of −0.0028 versus 0.0004). The rate
Table 2. Methylation status of VDAC2 in human sperm in NZ and IAS group. CpG:—C—phosphate—G—;
NZ: normozoospermia; IAS: idiopathic asthenospermia; Statistically significant differences from the control group (NZ) were represented with asterisks: *P < 0.05, **P < 0.01.

| Groups | Status of methylation | NZ Complete unmethylation (0%)** | NZ Mild methylation (0–20%)* | NZ Moderate methylation (20–80%)** | NZ Severe methylation (80–100%) | Total (N) |
|--------|-----------------------|---------------------------------|-------------------------------|----------------------------------|-------------------------------|-----------|
| NZ     | Complete unmethylation (0%)** | 74.07%(200/270) | 76.67%(207/270) | 75.19%(203/270) | 86.30%(233/270) | 86.67%(234/270) | 84.81%(229/270) | 90.37%(224/270) |
|        | Mild methylation (0–20%)* | 7.41%(20/270) | 8.15%(22/270) | 9.26%(25/270) | 6.67%(18/270) | 11.85%(32/270) | 10.74%(29/270) | 7.04%(19/270) |
|        | Moderate methylation (20–80%)** | 18.52%(50/270) | 15.19%(41/270) | 15.56%(42/270) | 7.04%(19/270) | 1.48%(4/270) | 4.44%(12/270) | 2.59%(7/270) |
|        | Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|        | Total (N) | 270 | 270 | 270 | 270 | 270 | 270 | 270 |

| Groups | Status of methylation | IAS Complete unmethylation (0%) | IAS Mild methylation (0–20%)* | IAS Moderate methylation (20–80%) | IAS Severe methylation (80–100%) | Total (N) |
|--------|-----------------------|---------------------------------|-------------------------------|----------------------------------|-------------------------------|-----------|
| IAS    | Complete unmethylation (0%) | 64.00%(160/250) | 69.20%(173/250) | 63.60%(159/250) | 80.80%(202/250) | 75.60%(189/250) | 72.80%(182/250) | 80.80%(202/250) |
|        | Mild methylation (0–20%)* | 3.60%(9/250) | 6.40%(16/250) | 4.00%(10/250) | 6.40%(16/250) | 6.00%(15/250) | 4.40%(11/250) | 8.80%(22/250) |
|        | Moderate methylation (20–80%) | 32.40%(81/250) | 24.40%(61/250) | 29.20%(73/250) | 12.80%(32/250) | 18.40%(46/250) | 22.80%(57/250) | 10.40%(26/250) |
|        | Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|        | Total (N) | 250 | 250 | 250 | 250 | 250 | 250 | 250 |

| Groups | Status of methylation | NZ Complete unmethylation (0%) | NZ Mild methylation (0–20%)* | NZ Moderate methylation (20–80%)** | NZ Severe methylation (80–100%) | Total (N) |
|--------|-----------------------|---------------------------------|-------------------------------|----------------------------------|-------------------------------|-----------|
| NZ     | Complete unmethylation (0%)** | 88.15%(238/270) | 80.74%(218/270) | 89.26%(241/270) | 77.78%(210/270) | 85.33(225/270) | 86.40%(216/270) |
|        | Mild methylation (0–20%)* | 8.15%(22/270) | 8.15%(22/270) | 8.15%(22/270) | 9.26%(25/270) | 10.00%(27/270) | 9.26%(25/270) |
|        | Moderate methylation (20–80%) | 3.70%(10/270) | 11.11%(30/270) | 2.59%(7/270) | 12.96%(35/270) | 3.70%(10/270) | 6.67%(18/270) | 1.11%(3/270) |
|        | Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|        | Total (N) | 270 | 270 | 270 | 270 | 270 | 270 | 270 |

| Groups | Status of methylation | IAS Complete unmethylation (0%) | IAS Mild methylation (0–20%)* | IAS Moderate methylation (20–80%) | IAS Severe methylation (80–100%) | Total (N) |
|--------|-----------------------|---------------------------------|-------------------------------|----------------------------------|-------------------------------|-----------|
| IAS    | Complete unmethylation (0%) | 81.60%(204/250) | 76.40%(191/250) | 85.20%(213/250) | 69.60%(174/250) | 72.80%(182/250) | 86.40%(216/250) |
|        | Mild methylation (0–20%)* | 8.00%(20/250) | 8.80%(22/250) | 10.40%(26/250) | 5.60%(14/250) | 24.80%(62/250) | 20.80%(52/250) | 4.00%(10/250) |
|        | Moderate methylation (20–80%) | 10.40%(26/250) | 14.80%(37/250) | 4.40%(11/250) | 24.80%(62/250) | 11.20%(28/250) | 20.80%(52/250) | 4.00%(10/250) |
|        | Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|        | Total (N) | 250 | 250 | 250 | 250 | 250 | 250 | 250 |
cells were washed twice with phosphate buffer (PBS), trypsinized with 0.25% trypsin (Gibco, Grand Island, USA), and seeded in a 6-well plate.

5-Aza-CdR was dissolved in 50 mg/ml 50% acetic acid, and the solutions were stored in ice until use according to the manufacturer's instructions. 5-Aza-CdR treatment was optimized to establish a working concentration range of $5 \mu\text{mol/L}$ to $15 \mu\text{mol/L}$. Cells were exposed to 5-Aza-CdR for 24 and 48 h to allow drug incorporation into DNA. Control samples were added with the same volume of solvent to determine whether VDAC2 was regulated by methylation.

**Total RNA Extraction and qRT-PCR.** After 5-Aza-CdR treatment for 24 and 48 h, GC-2spd cells were washed twice with PBS and lysed by Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. Briefly, 1 μg of RNA was reverse transfected, and 2 μl of cDNA was amplified as follows: 95 °C for 30s, 40 cycles at 95 °C for 5s, and 60 °C for 1 min. The primers for VDAC2 and β-actin are displayed in Table 4. Three replicates of each reaction were performed, and cycle threshold values were averaged. The reactions were performed and analyzed via an ABI 7900 system (Applied Biosystems, Carlsbad, USA).

**Plasmids and Promoter Reporter Constructs.** A psi_CHECK-2 vector was purchased from Novobio, Shanghai (Fig. 5A). The entire sequence of the predicted VDAC2 promoter region ($\sim 2000$ bp to +$1000$ bp) was correctly synthesized (Fig. 5B) and inserted into the psi_CHECK-2 vector between KpnI and NheI restriction enzyme cutting sites; the vector was named psi_CHECK-2-VDAC2. The product was transferred into competent DH5α cells, which were cultured overnight. Bacterial colonies were randomly picked for sequencing. Correct sequences were ensured after amplification with an automatic sequencer (Fig. 5C). A GenElute Plasmid Miniprep Kit was used for extraction and collection of recombinant plasmid according to the manufacturer’s instruction. The plasmid was stored at $-20$ °C until use.

**Dual-luciferase Reporter Assay.** Luciferase assays were performed according to the manufacturer’s protocol. GC-2spd cells were seeded into a 6-well plate at a density of $5 \times 10^5$ per well. Upon reaching 50–60% confluence, GC-2spd cells were transfected with psi_CHECK-2-VDAC2 and psi_CHECK-2-NC, which was used as negative control through Lipofectamine 2000 (Invitrogen, Carlsbad, USA). At 48 h after transfection, the cells were lysed and luciferase activity was examined via Dual-Luciferase Reporter Assay System (Promega E1910, Wisconsin, USA). The data were recorded on a luminometer (Tecan infinite M200 pro, Austria) and normalized by dividing firefly luciferase activity with that of Renilla luciferase. The data were then analyzed and graphed using Excel (Microsoft).

**DNA Extraction and Bisulfite Genomic Sequencing of the VDAC2 Promoter CpGs.** DNA was extracted from all semen samples using a genomic DNA isolation kit (Generay, Shanghai, China). Isolated genomic DNA was modified with the sodium bisulfite method using an Epitext Fast DNA Bisulfite Kit according to the manufacturer’s protocol (Qiagen 59824, Germany). The PCR primers for the predicted promoter region after bisulfite conversion were F: TTTAATATTTTG GTTAATATGGTGAAATTT and R: AAAACTCCCAAAGACATTACATCTATC. The reaction for mRNA detection was performed according to the following conditions: 95 °C for 4 min, 40 cycles at 94 °C for 30s, 50 °C for 30s, and 72 °C for 40s. The reactions were...
performed and analyzed via an ABI 7900 system. For sequence analysis after methylation, products were cloned into the pTG19-T vector (Generay, Shanghai, China) and 10 individual clones were sequenced.

### Statistical Analysis

Methylation status was categorized according to methylation degree into 4 types: complete unmethylation (no methylated CpGs), mild hypermethylation (0–20% methylated CpGs), moderate hypermethylation (20–80% methylated CpGs) and severe hypermethylation (80–100% methylated CpGs). Student’s t-test was performed to compare methylation status between the 2 groups. Correlation analysis was applied to evaluate the relationship between different methylation types and sperm parameters. Results of bisulfite genomic sequencing were analyzed via BiQ_Analyzer. All statistical data were presented as mean ± SD and analyzed using SPSS 20.0. *P* < 0.05 was considered statistically significant, and *P* < 0.01 was considered extremely significant.

### Table 4. PCR primers used in this study.

| Name   | Site       | Primer sequence (5′–3′)                                      | Annealing temp. (°C) | Product size (bp) | CpGs (n) |
|--------|------------|---------------------------------------------------------------|----------------------|-------------------|----------|
| CpG island-1 | -1337−1059 | F: TTTAATTTTGTGTTATAGGTGAAATTT  
R: AAAACTCCCAAAGACCTATGTCATC | 70.4                | 279                | 14       |
| CpG island-2 | -163+76    | F: TTATAATTTAAGAGGTGGTTGTT  
R: CTACCTCTTTTTCCACCTTATAAA | 70.1                | 250                | 12       |
| CpG island-3 | +123+476   | F: TTTTGGGTTGGGAAAGAAGA  
R: AACTACTAAACCTAAATCAAACAC | 70.4                | 354                | 37       |
| CpG island-4 | +630+953   | F: TTTAGGTITGTTGGAAGGATAG  
R: ACTAAAATCAAACACACAAAAAAA | 69.8                | 324                | 35       |
| CpG island-5 | +933+1229  | F: TTTTGTGTGTATTTTAGTTAT  
R: AACCTTAATTCCTTATATTCATC | 70.0                | 297                | 20       |
| VDAC2   | —          | F: AGAAGAGGCTCCTACGAA  
R: AAACAAAGGCCGTGATAGGTT | 68.9                | 100                | —        |
| β-actin | —          | F: TCACCCACAATGTGCCCCATCTACGA  
R: CAGCGGAACCGCTCATGGCAAATGG | 72.3                | 295                | —        |

#### Figure 5. Identification of the human VDAC2 gene promoter.

(A) psi_CHECK-2. (B) M: 3000 bp DNA Marker, 1–4 represent the brands of psi_CHECK-2-VDAC2 and replied with 5–8. The well of 1, 2, 3, 5, 6 and 7 were the fractional products of the VDAC2 promoter region; the well of 4 and 8 were the integrated products. (C) Partial sequence of the product of the recombinant VDAC2 promoter region.
References

1. Kurtz, M. P. et al. Semen parameters in adolescents with varicocele: association with testis volume differential and total testis volume. The journal of urology 193, 1843–1847, doi: 10.1016/j.juro.2014.10.111 (2015).

2. Cai, T. et al. Effect of human papillomavirus and Chlamydia trachomatis co-infection on sperm quality in young heterosexual men with chronic prostatitis-related symptoms. BJU international 113, 281–287, doi: 10.1111/bju.12244 (2014).

3. Draper, E. [Fertility disorders attributable to the use of diethylstilbestrol during intrauterine life. Rev Fr Gynecol Obstet 79, 297–300, 303–285 (1984).

4. Vandeckerkhove, P., Lilford, R., Vai, A. & Hughes, E. WITHDRAWN: Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. The Cochrane database of systematic reviews Cd000151, doi: 10.1002/14651858.cd000151 (1996).

5. Safarinejad, M. R., Safarinejad, S., Shafiei, N. & Safarinejad, S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. The journal of urology 188, 526–531, doi: 10.1016/j.juro.2012.03.131 (2012).

6. Dacheux, J. L. & Dacheux, F. New insights into epididymal function in relation to sperm maturation. Reproduction 147, R27–42, doi: 10.1530/rep-13-0420 (2014).

7. Benz, R. Porin from bacterial and mitochondrial outer membranes. CRC critical reviews in biochemistry 19, 145–190 (1985).

8. Schein, S. J., Colombini, M. & Finkenstein, A. Reconstitution in planar lipid bilayers of a voltage-dependent anion-selective channel obtained from paramecium mitochondria. The journal of membrane biology 30, 99–120 (1976).

9. Deckter, W. K., Bowles, K. R., Schatte, E. C., Toubin, J. A. & Craigen, W. J. Revised fine mapping of the human voltage-dependent anion channel loci by radiation hybrid analysis. Mammalian genome: official journal of the International Mammalian Genome Society 10, 1041–1042 (1999).

10. Deckter, W. K. & Craigen, W. J. The tissue-specific, alternatively spliced single ATG exon of the type 3 voltage-dependent anion channel gene does not create a truncated protein isoform in vivo. Molecular genetics and metabolism 70, 69–74, doi: 10.1006/mgme.2000.2987 (2000).

11. Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J. & Kormeyer, S. J. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science (New York, N.Y.) 301, 513–517, doi: 10.1126/science.1083995 (2003).

12. Rostovtseva, T. & Colombini, M. ATP flux is controlled by a voltage-gated channel from the mitochondrial outer membrane. The journal of biological chemistry 271, 28006–28008 (1996).

13. Benz, R. Permeation of hydrophilic solutes through mitochondrial outer membranes: review on mitochondrial porins. Biochimica et biophysica acta 1197, 167–196 (1994).

14. Gincel, D., Silberberg, S. D. & Shoshan-Barmatz, V. Modulation of the voltage-dependent anion channel (VDAC) by glutamate. Journal of bioenergetics and biomembranes 32, 371–583 (2000).

15. Shoshan-Barmatz, V., Israelson, A., Brdicka, D. & Sheu, S. S. The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Current pharmacetical design 12, 2249–2270 (2006).

16. Messina, A., Reina, S., Guarino, F. & De Pinto, V. VDAC isoforms in mammals. Biochimica et biophysica acta 1818, 1466–1476, doi: 10.1016/j.bbamem.2011.10.005 (2012).

17. Kwon, W. S., Park, Y. J., Mohamed el, S. A. & Pang, M. G. Voltage-dependent anion channels are a key factor of male fertility. Fertility and sterility 99, 354–361, doi: 10.1016/j.fertnstert.2012.09.021 (2013).

18. Liu, B. et al. Co-incubation of human spermatozoa with anti-VDAC antibody reduced sperm motility. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 33, 142–150, doi: 10.1159/000356657 (2014).

19. Hirsch, K. D. et al. Voltage-dependent anion-selective channels VDAC2 and VDAC3 are abundant proteins in bovine outer dense fibers, a cytoskeletal component of the sperm flagellum. The journal of biological chemistry 279, 15281–15288, doi: 10.1074/jbc.M104724200 (2004).

20. Liu, B., Wang, Z., Zhang, W. & Wang, X. Expression and localization of voltage-dependent anion channels (VDAC) in human spermatozoa. Biochemical and biophysical research communications 378, 366–370, doi: 10.1016/j.bbrc.2008.10.177 (2009).

21. Liu, B. et al. Analysis and difference of voltage-dependent anion channel mRNA in ejaculated spermatozoa from normozoospermic fertile donors and infertile patients with idiopathic asthenozoospermia. Journal of assisted reproduction and genetics 27, 719–724, doi: 10.1007/s10610-010-9466-8 (2010).

22. Sampson, M. J. et al. Immotile sperm and infertility in mice lacking mitochondrial voltage-dependent anion channel type 3. The journal of biological chemistry 276, 39206–39212, doi: 10.1074/jbc.M104724200 (2001).

23. Yuan, J. et al. MYBL2 guides autophagy suppressor VDAC2 in the developing ovary to inhibit autophagy through a complex of VDAC2-BECN1-BCL2L1 in mammals. Autophagy 11, 1088–1098, doi: 10.1002/ajau.21508 (2015).15.04970 (2015).

24. Piroli, G. G. et al. Succination is Increased on Select Proteins in the Brainstem of the NADH dehydrogenase (ubiquinone) Fe-S protein 4 (Ndufs4) Knockout Mouse, a Model of Leigh Syndrome. Molecular & cellular proteomics : MCP 15, 445–461, doi: 10.1074/mcp.M115.051516 (2016).

25. Maurya, S. R. & Mahalakshmi, R. VDAC-2: Mitochondrial outer membrane regulator masquerading as a channel? BJU International 113, 281–287, doi: 10.1111/bju.12244 (2014).

26. Zhang, L. et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB activation. Nature 481, 204–208, doi: 10.1038/nature10690 (2012).

27. Yang, J., Lior-Hoffmann, L., Wang, S., Zhang, Y. & Broyle, S. DNA cytosine methylation: structural and thermodynamic characterization of the epigenetic marking mechanism. Biochemistry 52, 2828–2838, doi: 10.1021/bi010016k (2013).

28. Svedruzic, Z. M. & Reich, N. O. The mechanism of target base attack in DNA cytosine carbon 5 methylation. Biochemistry 43, 11460–11473, doi: 10.1021/bi0496743 (2004).

29. Maurya, S. R. & Mahalakshmi, R. Modulation of human mitochondrial voltage-dependent anion channel 2 (hVDAC2)-structural stability by cysteine-assisted barrel-lipid interactions. The journal of biological chemistry 288, 25584–25592, doi: 10.1074/jbc.M113.493692 (2013).

30. Li, B. et al. Altered DNA methylation patterns of the H19 differentially methylated region and the DAZL gene promoter are associated with defective human sperm. PloS one 8, e71215, doi: 10.1371/journal.pone.0071215 (2013).

Acknowledgements

This work is supported by grant from the National Natural Science Foundation of China (81200467; 81270685) and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (1X10231802).

Author Contributions

Conceived and designed the experiments: W.Z., L.B., and X.A. Data acquisition: F.J. and Z.J. Data analysis and interpretation: H.Y., X.A., C.W., and Z.K. Prepare figures: X.A., Z.K., T.M., and C.W. Contributed materials/analysis tools: Z.J., X.W., S.S., and W.H. Wrote and revised the paper: X.A., H.Y., Z.J., L.B., and W.Z.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Xu, A. et al. Abnormal Hypermethylation of the VDAC2 Promoter is a Potential Cause of Idiopathic Astenospermia in Men. Sci. Rep. 6, 37836; doi: 10.1038/srep37836 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016